Highest-materiality recent filing
Novanta Q2 2026 revenue up 10% to $266M; adjusted EPS up 17% to $0.89
GAAP revenue $265.8M, up 10% YoY from $241.0M; net income $12.5M vs $4.5M.
Acquired Riverpoint Medical for ~$1.2B cash at closing; additional $250M milestone payment due by Jan 8, 2027.
Novanta raises $300M via private placement of 2.1M shares at $140 each
Sold 2,142,857 common shares at $140.00 each for gross proceeds of ~$300M.
Upfront cash consideration of $1.2B; milestone payment of $250M due Q1 2027.
Novanta Q1 revenue up 10% to $258M, adjusted EPS $0.81, net income $21M
GAAP revenue $257.7M (+10% YoY); GAAP net income $21.1M (flat).
Novanta Q4 revenue $258M (+9% YoY), adjusted EPS $0.91 (+20% YoY)
GAAP revenue $258.3M in Q4 2025, up 9% YoY; GAAP diluted EPS $0.45.
Novanta closes $632.5M tangible equity units offering; amends credit agreement
Issued 12,650,000 Units at $50.00 each, including full over-allotment exercise.
Novanta board authorizes additional $200M share repurchase; total capacity $231M
Board approved $200M additional common share repurchase authorization on Sept 17, 2025.
Novanta Q2 2025 GAAP EPS falls 68% to $0.12; Adj. EPS rises to $0.76 on 2% revenue growth
GAAP revenue $241.0M (+2% YoY); GAAP net income $4.5M vs $13.8M; GAAP diluted EPS $0.12 vs $0.38.
Novanta Reports Q4 and Full Year 2024 Results: Revenue Up 13% in Q4, 8% for Full Year
Q4 2024 revenue increased 13% to $238M; GAAP diluted EPS $0.46, adjusted EPS $0.76.
Novanta recasts segment reporting into Automation Enabling Technologies and Medical Solutions
Two new segments replace prior three-segment structure (Precision Medicine & Manufacturing, Robotics & Automation, Medical Solutions).
Novanta Q3 2024 revenue up 10% to $244M; GAAP EPS $0.53 vs $0.59 a year ago
Revenue $244.4M, +10% YoY from $221.5M.
Novanta Q2 2024 revenue up 2.8% to $236M, but GAAP EPS falls 34% to $0.38
Revenue $235.9M (+2.8% YoY); GAAP net income $13.8M vs $20.9M in Q2 2023.
Novanta completes acquisition of Motion Solutions; draws $198M under credit facility
Acquired 100% of Motion Solutions capital stock for ~$192.2M using revolving credit facility draw of $198M.
Novanta to acquire Motion Solutions for $189M cash; expected close Q1 2024
Purchase price $189M in cash, financed with cash on hand and revolving credit facility.
Novanta Q2 revenue up 7% to $229.5M; GAAP EPS $0.58, adj. EPS $0.80
GAAP revenue $229.5M, +7% YoY from $215.4M; operating income $32.2M vs $23.3M.
Novanta Q3 revenue up 26% to $223M; raises FY2022 guidance
GAAP revenue $223M, +26% YoY; diluted EPS $0.63, +66% YoY.
Novanta Q2 2022: revenue up 29% to $215M; EPS $0.49; raises full-year guidance
GAAP revenue $215.4M (+29% YoY); operating income $23.3M.
Novanta Q1 2022 revenue up 26% to $204M; adjusted EPS $0.73
GAAP revenue $204.2M, up 26% YoY from $162.6M; GAAP net income $18.8M.
Novanta FY2021 revenue $707M (+20% YoY), adjusted EPS $2.62 (+34% YoY)
Full year 2021 GAAP revenue of $706.8M, up 20% from $590.6M in 2020.
Novanta Q3 revenue $177.7M (+24% YoY); adj. EPS $0.75, raises FY guidance
GAAP revenue $177.7M, up 24% from $142.9M in Q3 2020.
Mr. Burke succeeds Peter Chang, Chief Accounting Officer and Corporate Controller of the Company, who departed from the role effective August 22, 2024.
On August 22, 2024, John Burke, formerly Vice President of Global Accounting for Novanta Inc. (the “Company”), was appointed Chief Accounting Officer of Novanta Inc. and assumed the role of principal accounting officer.
On August 1, 2024, Novanta Inc. (the “Company”) announced that Brian Young, Chief Human Resources Officer (“CHRO”) of the Company, would no longer serve as the CHRO, effective on November 1, 2024, or such earlier date as may be agreed between Mr. Young and determined by the Company.
On July 11, 2024, Katherine A. Owen resigned as a member of the Board of Directors (the “Board”) of Novanta Inc. (the “Company”) and the Audit Committee of the Board, effective immediately.
On July 11, 2024, the Board elected Mary Katherine (Mary Kay) Ladone to the Board to fill the vacancy created by Ms. Owen’s resignation, effective July 11, 2024.
On July 26, 2022, the Board of Directors (the “Board”) of the Company elected Barbara B. Hulit to the Board to fill an existing vacancy, effective July 26, 2022.
On July 26, 2022, Ira J. Lamel resigned as a director of Novanta Inc. (the “Company”), effective immediately.
On June 28, 2022, the Board of Directors (the “Board”) of the Company elected Darlene J. S. Solomon, Ph.D., to the Board to fill an existing vacancy, effective June 28, 2022.
On June 28, 2022, Brian King resigned as a director of Novanta Inc. (the “Company”), effective immediately.
On November 6, 2021, Deborah DiSanzo, a member of the Board of Directors (the “Board”) of Novanta Inc. (the “Company”), informed the Company of her decision to resign from the Board, effective February 28, 2022, in order to focus her attention on her responsibilities as the President of Best Buy Health and other professional responsibilities.
Max materiality 0.90 · Median 0.55 · Most common event earnings